^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    c-MET-targeted antibody-drug conjugate

    Related drugs:
    3d
    A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (ChiCTR2600116886)
    P2/3, N=688, Not yet recruiting, Shanghai Chest Hospital; Shanghai Chest?Hospital
    New P2/3 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • telisotuzumab adizutecan (ABBV-400) • simmitinib (SYHA1817)
    3d
    A First-In-Human, Multicenter, Open-Label Phase I/II Investigational Study to Evaluate the Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of KY-0301 as monotherapy or combined with other anticancer agents in Patients with advanced Solid Tumors (ChiCTR2600116103)
    P1/2, N=120, Recruiting, Shanghai East Hospital; Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR wild-type • MET exon 14 mutation • KRAS wild-type • RAS wild-type • ROS1 fusion • ROS1 rearrangement • MET mutation • NTRK fusion
    8d
    Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer (clinicaltrials.gov)
    P1/2, N=105, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial
    8d
    A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection (clinicaltrials.gov)
    P1/2, N=465, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P1/2 trial
    14d
    Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 (clinicaltrials.gov)
    P1, N=302, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    telisotuzumab adizutecan (ABBV-400) • itraconazole
    18d
    A Study of HS-20122 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1050, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    19d
    A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=23, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=260 --> 23
    Enrollment closed • Enrollment change
    25d
    Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations (clinicaltrials.gov)
    P1/2, N=252, Recruiting, AbbVie | N=132 --> 252
    Enrollment change • Adverse events • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR wild-type
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • telisotuzumab adizutecan (ABBV-400)
    27d
    Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P2 trial
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • MET overexpression • EGFR exon 20 mutation
    |
    CONFIRM anti-Total c-MET (SP44) Rabbit Monoclonal Primary Antibody • VENTANA® MET (SP44) RxDx Assay
    |
    Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv) • simmitinib (SYHA1817)
    28d
    A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=67, Completed, RemeGen Co., Ltd. | N=32 --> 67 | Trial primary completion date: May 2025 --> Dec 2025 | Active, not recruiting --> Completed
    Trial completion • Enrollment change • Trial primary completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET positive
    |
    RC108
    28d
    A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor (clinicaltrials.gov)
    P2, N=29, Completed, RemeGen Co., Ltd. | Active, not recruiting --> Completed | N=240 --> 29
    Trial completion • Enrollment change
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET positive
    |
    RC108
    1m
    Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review. (PubMed, Thorac Res Pract)
    In phase Ib studies, TV-t combined with osimertinib achieved a 50% ORR and 7.4-month PFS, while TV-t with nivolumab, the median PFS was 7.2 months, but ORR was low (7.4%). TV-t demonstrated promising efficacy and tolerability in patients, highlighting its clinical potential. However, further studies are needed to confirm its survival advantage, the durability of response, and safety profile, and to establish its long-term value and support its integration into routine clinical practice.
    Journal • PD(L)-1 Biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR wild-type • MET exon 14 mutation • MET overexpression
    |
    Opdivo (nivolumab) • Tagrisso (osimertinib) • Emrelis (telisotuzumab vedotin-tllv)